An Open Label Randomized Phase II Study of SOM230 and Everolimus in Castrate-Resistant, Chemotherapy-Naive Prostate Cancer Patients.

Trial Profile

An Open Label Randomized Phase II Study of SOM230 and Everolimus in Castrate-Resistant, Chemotherapy-Naive Prostate Cancer Patients.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 17 Jul 2015

At a glance

  • Drugs Pasireotide (Primary) ; Everolimus
  • Indications Prostate cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 14 Jul 2015 Planned End Date changed from 1 Jun 2016 to 1 Jun 2018 as per ClinicalTrials.gov record.
    • 14 Jul 2015 Status changed from recruiting to discontinued as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top